Article
UPDATED: Vivek Ramaswamy's Metavant hits a brick wall, abandoning a lead program for diabetes. An
Rating:
0.0
Views:
118
Likes:
1
Library:
1
Just a few years after Vivek Ramaswamy's epic Alzheimer's fail, another one of his startups is cutting its losses because of a high-risk endeavor — this time on the diabetes front — didn't pan out. Metavant, Ramaswamy's biotech #7, has decided not to advance its lead candidate imeglimin into Phase
Rate This Post
-
Education
-
Communication
-
Entertainment
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value